Alexandria Hammond
Stock Analyst at B of A Securities
(2.40)
# 2,472
Out of 4,761 analysts
14
Total ratings
60%
Success rate
-1.06%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Alexandria Hammond
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AKRO Akero Therapeutics | Upgrades: Buy | $35 → $63 | $51.84 | +21.53% | 2 | Jan 30, 2025 | |
| REGN Regeneron Pharmaceuticals | Initiates: Outperform | $1,150 | $700.33 | +64.21% | 1 | Nov 15, 2024 | |
| PFE Pfizer | Initiates: Underperform | $25 | $26.30 | -4.94% | 1 | Nov 15, 2024 | |
| MRNA Moderna | Initiates: Underperform | $40 | $35.53 | +12.58% | 1 | Nov 15, 2024 | |
| MRK Merck & Co. | Initiates: Peer Perform | n/a | $89.50 | - | 1 | Nov 15, 2024 | |
| LLY Eli Lilly and Company | Initiates: Outperform | $1,000 | $873.68 | +14.46% | 1 | Nov 15, 2024 | |
| JNJ Johnson & Johnson | Initiates: Outperform | $190 | $162.30 | +17.07% | 1 | Nov 15, 2024 | |
| GILD Gilead Sciences | Initiates: Outperform | $110 | $109.95 | +0.05% | 1 | Nov 15, 2024 | |
| BMY Bristol-Myers Squibb Company | Initiates: Peer Perform | n/a | $55.83 | - | 1 | Nov 15, 2024 | |
| BIIB Biogen | Initiates: Peer Perform | n/a | $140.64 | - | 1 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $205 | $202.08 | +1.44% | 1 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underperform | $150 | $336.23 | -55.39% | 1 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $30 | $11.06 | +171.25% | 1 | Apr 22, 2024 |
Akero Therapeutics
Jan 30, 2025
Upgrades: Buy
Price Target: $35 → $63
Current: $51.84
Upside: +21.53%
Regeneron Pharmaceuticals
Nov 15, 2024
Initiates: Outperform
Price Target: $1,150
Current: $700.33
Upside: +64.21%
Pfizer
Nov 15, 2024
Initiates: Underperform
Price Target: $25
Current: $26.30
Upside: -4.94%
Moderna
Nov 15, 2024
Initiates: Underperform
Price Target: $40
Current: $35.53
Upside: +12.58%
Merck & Co.
Nov 15, 2024
Initiates: Peer Perform
Price Target: n/a
Current: $89.50
Upside: -
Eli Lilly and Company
Nov 15, 2024
Initiates: Outperform
Price Target: $1,000
Current: $873.68
Upside: +14.46%
Johnson & Johnson
Nov 15, 2024
Initiates: Outperform
Price Target: $190
Current: $162.30
Upside: +17.07%
Gilead Sciences
Nov 15, 2024
Initiates: Outperform
Price Target: $110
Current: $109.95
Upside: +0.05%
Bristol-Myers Squibb Company
Nov 15, 2024
Initiates: Peer Perform
Price Target: n/a
Current: $55.83
Upside: -
Biogen
Nov 15, 2024
Initiates: Peer Perform
Price Target: n/a
Current: $140.64
Upside: -
Nov 15, 2024
Initiates: Outperform
Price Target: $205
Current: $202.08
Upside: +1.44%
Apr 22, 2024
Initiates: Underperform
Price Target: $150
Current: $336.23
Upside: -55.39%
Apr 22, 2024
Assumes: Buy
Price Target: $30
Current: $11.06
Upside: +171.25%